Giant Biogene

Pre-IPO Giant Biogene (2367 HK) - Some Unstable Factors

130 Views26 Oct 2022 21:06
Giant Biogene's marketing-driven development will lead to low margins. It takes time for recombinant collagen to replace animal-derived collagen. Lacking the second growth point cast doubts on outlook
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
(Paid Plans Only)